Superluminal partners with Eli Lilly to advance AI-driven small molecule therapeutics for cardiometabolic diseases.

Having backed Superluminal Medicines’ series A last year, Eli Lilly has now signed a $1.3 billion pact with the G ...

Superluminal Medicines, a drug discovery company integrating AI/ML, protein dynamics, and structural biology announced a collaboration with Eli ...

"Eli Lilly seeks more GPCR weight loss drugs in $1.3bn research deal" was originally created and published by Pharmaceutical ...